MDXG
MiMedx Group, Inc.
NASDAQ · Healthcare · Biotechnology · US
$4.57
+3.16%Year over year
Reported trailing growth
- Revenue
- -2.4%
- EBITDA
- -57.5%
- EBIT
- -79.6%
- EPS
- -81.9%
- Free cash flow
- -22.0%
- Operating cash flow
- -20.6%
Forward estimates
Based on analyst estimates
- Revenue
- -9.8%
- EBITDA
- -41.0%
- EPS
- +6.3%
Three-year CAGR
- Revenue
- +16.1%
- EBITDA
- +43.1%
- EBIT
- +31.2%
- Net income
- -15.1%
- EPS
- -17.1%
- Free cash flow
- +71.6%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026